Risk of fractures and diabetes medications: a nationwide cohort study
Authors:
- 14 April 2016
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 27 (9) , 2709-2715
Abstract
Summary The effects of diabetes medications on risk of fracture were investigated using the South Korea nationwide claims database. We demonstrated that the use of dipeptidyl peptidase-4 inhibitor could be associated with decreased risk of fracture. Thiazolidinedione use was associated with about 60 % increased risk of fracture in real clinical practice. Introduction The effects of diabetes medication on fracture have important clinical health consequences, since most diabetes patients are at high risk of fracture. We aimed to investigate the effect of diabetes medication on fracture risk. Methods The nationwide medical claim database in South Korea was investigated. Among 2,886,555 subjects with antidiabetes prescriptions, 207,558 subjects aged 50 years and older, who initiated diabetes medication from 2008 to 2011, were analyzed. The subjects were classified based on diabetes medication classes: non-user (insufficient exposure), metformin (MET), sulfonylurea (SU), alpha-glucosidase inhibitor (AGI), MET + SU, MET + thiazolidinedione (TZD), MET + dipeptidyl peptidase-4 inhibitor (DPP4-I), and SU + TZD. Results A total of 5996 fractures were observed. The fracture rate varied significantly across type of diabetes medications, with MET + DPP4-I combination group having the lowest rate and SU + TZD combination group having the highest rate. Compared to non-users, MET + DPP4-I inhibitor combination group had significantly reduced composite fracture risk (hazard ratio (HR) = 0.83, P = 0.025) and significantly reduced vertebral fracture risk (HR = 0.73, P = 0.013) in the unadjusted analysis. Compared to MET + SU users, MET + DPP4-I users showed a trend of lower non-vertebral fracture risk (HR = 0.82, P = 0.086) after adjusting for all confounding variables. Patients using TZD had significantly increased risk of fracture (HR = 1.59, P < 0.001) compared with patients not using TZDs adjusting for all confounding variables. Conclusions The results of this nationwide study showed a trend that DPP4 inhibitor might have a protective effect on bone metabolism compared with SU, when added to MET. Clinicians should take these results into consideration when prescribing diabetes medication, especially in elderly patients or those at high risk or fracture.Keywords
Funding Information
- Korea Academy of Medical Sciences (2011)
This publication has 31 references indexed in Scilit:
- Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugsPharmacoepidemiology and Drug Safety, 2015
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Bisphosphonate use and subsequent hip fracture in South KoreaOsteoporosis International, 2013
- Dipeptidyl Peptidase-4 Inhibitors and Bone FracturesDiabetes Care, 2011
- Incidence and Mortality Following Hip Fracture in KoreaJournal of Korean Medical Science, 2011
- Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant StatesCalcified Tissue International, 2009
- Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic MenDiabetes Care, 2007
- Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone massBone, 2007
- Disassociation of bone resorption and formation by GLP-2Bone, 2007
- Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in cultureEuropean Journal of Pharmacology, 2006